Efficacy and safety of perindopril arginine + amlodipine in hypertension

Journal of the American Society of Hypertension

Volumn 9, Issue 4, 2015, Pages 266-274

  Elliott, William J ^a   Whitmore, Jennifer ^b   Feldstein, Jeffrey D ^b,c   Bakris, George L ^d  

^a Pacific Northwest University of Health Sciences   (United States)

^b XOMA Corporation   (United States)

^c Symplmed   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Besylate; erbumine; pedal edema

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE PLUS PERINDOPRIL; PERINDOPRIL TERT BUTYLAMINE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; PERINDOPRIL; POTASSIUM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOOT EDEMA; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; URINARY TRACT DISEASE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; EDEMA; GLOMERULUS FILTRATION RATE; MIDDLE AGED; MULTICENTER STUDY;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PERINDOPRIL; POTASSIUM; PROSPECTIVE STUDIES;

EID: 84928423414     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2015.01.012     Document Type: Article

References (32)

1. P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfard, and J. Handler 2014 Evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
2. Canadian Hypertension Education Program (CHEP) 2014 Recommendations. Available at: http://www.hypertension.ca/en/chep, Accessed on March 5, 2014.
3. Higgins B, Williams B, Williams H, Northedge J, Crimmins J, Lovibond K, et al. The Guideline Development Groups, National Collaborating Centres, and NICE Project Team. United Kingdom National Health Service: National Institute for Health and Clinical Excellence. Hypertension: Clinical management of hypertension in adults (CG127), issued February 2011. Available at: http//www.nice.org.uk/guidance/cg127, accessed December 18, 2013.
4. M.A. Weber, E.L. Schiffrin, W.B. White, S. Mann, L.H. Lindholm, and J.G. Kenerson Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension J Clin Hypertens (Greenwich) 16 2014 14 26
5. G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, and M. Böhm 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
7. B. Dahlöf, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, and M. Caulfield Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906
8. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, V. Shi ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
9. R. Cooper-DeHoff, and W.J. Elliott Generic drugs for hypertension: are they really equivalent? Curr Hypertens Rep 15 2013 340 345
10. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment and control of hypertension: 1998-2008 JAMA 303 2010 2043 2050
11. M. Joffres, E. Falaschetti, C. Gillespie, C. Robitaille, F. Loustalot, and N. Poulter Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA, and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study BMJ Open 3 2013 e003423
12. M.G. Jaffe, G.A. Lee, J.D. Young, S. Sidney, and A.S. Go Improved blood pressure control associated with a large-scale hypertension program JAMA 310 2013 699 705
13. A.H. Gradman, J.N. Basile, B.L. Carter, G.L. Bakris American Society of Hypertension Writing Group Combination therapy in hypertension J Am Soc Hypertens 4 2010 42 50
14. W.J. Elliott Should there be any reluctance to initiate combination antihypertensive therapy in patients with blood pressure of 160/100 mm Hg or higher? G.L. Bakris, Therapeutic Strategies in Hypertension 2006 Clinical Publishing, Ltd Oxford, United Kingdom 85 102
15. A. Patel the ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
16. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
17. J. Cheng, W. Zhang, X. Zhang, F. Han, X. Li, and X. He Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis JAMA Intern Med 174 2014 773 785
18. W.J. Elliott Rationale for a single-pill combination of perindopril arginine and amlodipine besylate J Am Soc Hypertens 2015 [e-pub ahead of print]
19. T. Tejada, A. Fornoni, O. Lenz, and B.J. Materson Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide? Curr Hypertens Rep 9 2007 284 290
20. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr. National High Blood Pressure Education Program Coordinating Committee Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
21. K.A. Jamerson, O. Nwose, L. Jean-Louis, L. Schofield, D. Purkavastha, and M. Baron Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension Am J Hypertens 17 2004 495 501
22. T. Philipp, R.D. Glazer, M. Wernsing, and J. Yen Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension J Am Soc Hypertens 5 2011 417 424
23. S. Chrysant, M. Melino, S. Karki, J. Lee, and R. Heyrman The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 30 2008 587 604
24. T.W. Littlejohn 3rd, C.R. Majul, R. Olvera, M. Seeber, M. Kobe, and R. Guthrie Results of treatment with telmisartan-amlodipine in hypertensive patients J Clin Hypertens (Greenwich) 11 2009 207 213
25. M.J. Brown, G.T. McInnes, C.C. Papst, J. Zhang, and T.M. MacDonald Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial Lancet 377 2011 312 320
26. G. Mancia, R. Asmar, C. Amodeo, J.J. Mourad, S. Taddei, and M.A. Gamba Comparison of single-pill strategies first-line in hypertension: perindopril/amlodipine versus valsartan/amlodipine J Hypertens 33 2015 401 411
27. L. Ruilope, and A. Schaefer The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension Adv Ther 30 2013 1086 1099
28. S. Bangalore, S. Kumar, and F.H. Messerli Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference Am J Med 123 2010 1016 1030
29. H. Makani, S. Bangalore, J. Romero, O. Wever-Pinzon, and F.H. Messerli Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Am J Med 124 2011 128 135
30. M. Weber, S. Julius, K.E. Kjeldsen, H.R. Brunner, S. Ekman, and L. Hansson Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial Lancet 363 2004 2049 2051
31. J.A. Staessen, L. Thijs, R. Fagard, H. Celis, W.H. Birkenhäger, C.J. Bulpitt Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial J Hypertens 22 2004 847 857
32. W.J. Kostis, L. Thijs, T. Richart, J.B. Kostis, and J.A. Staessen Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications Hypertension 56 2010 1060 1068